title: Systemic vasculitis associated with anti-neutrophil cytoplasmic antibodies against bactericidal/permeability increasing protein.
abstract: Myeloperoxidase- and proteinase 3-anti-neutrophil cytoplasmic antibodies (ANCAs) are often negative in cases in which systemic vasculitis is highly suspected. We herein present a case of bactericidal/permeability increasing protein (BPI)-ANCA-positive systemic vasculitis. This case highlights the possible role of BPI-ANCA in the pathogenesis of systemic vasculitis as well as the possible use of BPI as a diagnostic tool. The accumulation of further case-based reports is expected to shed some light on the pathogesis of systemic vasculitis.
authors.affiliation: Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Japan.
authors.forename: Atsuro
authors.initials: A
authors.lastname: Fukuhara
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Tanino
authors.forename: Suguru
authors.initials: S
authors.lastname: Sato
authors.forename: Taeko
authors.initials: T
authors.lastname: Ishii
authors.forename: Takefumi
authors.initials: T
authors.lastname: Nikaido
authors.forename: Kenya
authors.initials: K
authors.lastname: Kanazawa
authors.forename: Junpei
authors.initials: J
authors.lastname: Saito
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishida
authors.forename: Makoto
authors.initials: M
authors.lastname: Kanno
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Watanabe
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Munakata
mesh_terms: D000368:Aged; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D000918:Antibody Specificity; D023181:Antimicrobial Cationic Peptides / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology*; D001798:Blood Proteins / Q000276:immunology*; D029481:Bronchitis, Chronic / Q000150:complications; D003520:Cyclophosphamide / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D005921:Glomerulonephritis / Q000209:etiology; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D007166:Immunosuppressive Agents; D017563:Lung Diseases, Interstitial / Q000000981:diagnostic imaging / Q000209:etiology; D010996:Pleural Effusion / Q000209:etiology; D011009:Pneumoconiosis / Q000150:complications; D011239:Prednisolone / Q000627:therapeutic use; D011859:Radiography
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D023181:Antimicrobial Cationic Peptides; D001324:Autoantigens; D001798:Blood Proteins; D007166:Immunosuppressive Agents; C021623:bactericidal permeability increasing protein; D003520:Cyclophosphamide; D011239:Prednisolone